Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Roche infectious diseases pipeline Holistic portfolio coverage is a key medical value Viral Hepatitis + STDs Pregnancy + Transplant Respiratory Vector Borne Roche Donor Screening Anti-HCV HBsAg Anti-HBc HIV combi PT HIV Duo Syphilis Vaccination Panel Anti-HBs Rubella IgG Anti-HAV >6 more medical value solutions Gastrointestinal cDiff >3 more medical value solutions Antimicrobial Stewardship MTB-RIF/INH >6 more medical value solutions HIV-1 CT/NG CMV Flu A/B/RSV HBV TV/MG HSV-1/2/VZV MTB Zika IgG Zika IgM HCV HPV EBV ΜΑΙ HIV-1/2 Qual HCV DUO BKV MPLX Respiratory Dengue IgG Dengue IgM Anti-HEV IgG CMV IgG >5 more high medical Dengue Ag Anti-HEV IgM CMV IgM value solutions Chik IgG CMV Avidity Chik IgM Toxo IgG Lyme IgG Anti-HAV Anti-HAV IgM HBsAg HBsAg confirmatory HBsAg quant Anti-HBs Anti-HBc Anti-HBc IgM Anti-HBe HBeAg Anti-HCV HIV combi PT HIV DUO HIV confirmatory HTLV I/II Syphilis Genital Ulcer Panel Vaginal Discharge Panel Mycoplasma Panel HBeAg quant Anti-HBc quant >10 more medical value solutions Toxo IgM Toxo Avidity EBV EBNA IgG EBV VCA IgG EBV IgM Adeno Quant HSV-1/2/VZV >3 more medical value solutions Chagas HTLV I/II Lyme IgM CMV IgG >2 more medical MPX value solutions WNV DPX HEV CHIKV/DENV Zika (US-IVD) Babesia Zika (CE-IVD) >2 more medical value solutions RPR HSV-1 IgG HSV-2 IgG IA: Investigational Assay, US-IVD: Exclusive to US Sepsis PCT IL-6 IL-6 US neonatal & adult New Early Sepsis Marker Digital Decision Support On market In development Considered 50
View entire presentation